368 related articles for article (PubMed ID: 29510676)
1. Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
Jin BF; Yang F; Ying XM; Gong L; Hu SF; Zhao Q; Liao YD; Chen KZ; Li T; Tai YH; Cao Y; Li X; Huang Y; Zhan XY; Qin XH; Wu J; Chen S; Guo SS; Zhang YC; Chen J; Shen DH; Sun KK; Chen L; Li WH; Li AL; Wang N; Xia Q; Wang J; Zhou T
BMC Cancer; 2018 Mar; 18(1):259. PubMed ID: 29510676
[TBL] [Abstract][Full Text] [Related]
2. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
3. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
7. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer.
Feng A; Tu Z; Yin B
Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
[TBL] [Abstract][Full Text] [Related]
9. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
[TBL] [Abstract][Full Text] [Related]
11. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
12. Expression of DR5 and c‑FLIP proteins as novel prognostic biomarkers for non‑small cell lung cancer patients treated with surgical resection and chemotherapy.
Zheng H; Zhang Y; Zhan Y; Liu S; Lu J; Wen Q; Fan S
Oncol Rep; 2019 Dec; 42(6):2363-2370. PubMed ID: 31638235
[TBL] [Abstract][Full Text] [Related]
13. Loss of β-arrestin1 expression predicts unfavorable prognosis for non-small cell lung cancer patients.
Ma H; Wang L; Zhang T; Shen H; Du J
Tumour Biol; 2016 Jan; 37(1):1341-7. PubMed ID: 26293896
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
15. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis.
Luo X; Zang X; Yang L; Huang J; Liang F; Rodriguez-Canales J; Wistuba II; Gazdar A; Xie Y; Xiao G
J Thorac Oncol; 2017 Mar; 12(3):501-509. PubMed ID: 27826035
[TBL] [Abstract][Full Text] [Related]
17. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
18. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
[TBL] [Abstract][Full Text] [Related]
20. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]